一种新的心脏装置在早期试验中减少了危险的心律失常,没有严重的副作用。 A new heart device reduced dangerous arrhythmias in early trials with no serious side effects.

Field Medical 的 FieldForce™ 脉冲场消融系统的一项首次人体试验显示，82% 的患者在六个月时没有室性心动过速或颤动复发，心律失常负担减轻了 98%，并且没有与治疗相关的并发症。 A first-in-human trial of Field Medical’s FieldForce™ Pulsed Field Ablation System showed 82% of patients were free from ventricular tachycardia or fibrillation recurrence at six months, with a 98% reduction in arrhythmia burden and no therapy-related complications. 非热系统有效地针对深度疤痕组织,这是长期的治疗挑战。 The nonthermal system effectively targeted deep scar tissue, a longstanding treatment challenge. 美国食品和药物管理局授予突破性设备名称,并将该设备纳入其TAP试点计划. The FDA granted Breakthrough Device designation and included the device in its TAP Pilot Program. 预计2026年初将有关于心房动的早期可行性数据. Early feasibility data for atrial fibrillation use is expected in early 2026.